Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2

First-generation vaccines against SARS-CoV-2 do not provide adequate immune protection. Therefore, we engineered a divalent gene construct combining the receptor-binding domain (RBD) of the spike protein and the immunodominant region of the viral nucleocapsid. This fusion protein was produced in eit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hevesi, Zsofia, Gerges, Daniela Anna, Kapps, Sebastian, Freire, Raimundo, Schmidt, Sophie, Pollak, Daniela D., Schmetterer, Klaus, Frey, Tobias, Lang, Rita, Winnicki, Wolfgang, Schmidt, Alice, Harkany, Tibor, Wagner, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028954/
https://www.ncbi.nlm.nih.gov/pubmed/35455265
http://dx.doi.org/10.3390/vaccines10040516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028954/
https://www.ncbi.nlm.nih.gov/pubmed/35455265
http://dx.doi.org/10.3390/vaccines10040516

Ejemplares similares